New Options For Acute Myeloid Leukemia (AML) Relapse: Combination Therapies with Gilteritinib

Published Apr 1, 2020

New Options For Acute Myeloid Leukemia (AML) Relapse: Combination Therapies with Gilteritinib

×
NOW
PLAYING
AML - Initial Treatment Overview
NOW
PLAYING
Understanding the Phases of AML Treatment
NOW
PLAYING
Differentiation Syndrome In Acute Myeloid Leukemia Patients
NOW
PLAYING
Acute Myeloid Leukemia: Making Treatment Decisions
NOW
PLAYING
The Benefits of Combination Drug Therapy Using Ventecolax for AML

Relapse : Symptoms & Diagnosis

SEE MORE   

  • Relapse is a part of the journey for many AML patients
  • The timing of relapse will be a big part of making treatment decisions
  • Monitoring health after initial treatment is crucial for people with AML

Relapse : Symptoms & Diagnosis

  • Relapse is a part of the journey for many AML patients
  • The timing of relapse will be a big part of making treatment decisions
  • Monitoring health after initial treatment is crucial for people with AML

Relapse : Exploring the Options

SEE MORE   

  • Drugs such as Ivosidenib or Enasidenib can be given to help achieve remission in patients with relapsed AML
  • Recently approved drugs, like FLT3-inhibitor Gilteritinib, have also shown great promise in treating relapsed disease

Relapse : Exploring the Options

  • Drugs such as Ivosidenib or Enasidenib can be given to help achieve remission in patients with relapsed AML
  • Recently approved drugs, like FLT3-inhibitor Gilteritinib, have also shown great promise in treating relapsed disease
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.